-+ 0.00%
-+ 0.00%
-+ 0.00%

LANTERN PHARMA'S SUBSIDIARY, STARLIGHT THERAPEUTICS, ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION CLEARANCE OF IND FOR PHASE IB/2A GLIOBLASTOMA MULTIFORME (GBM) TRIAL

Reuters·08/06/2025 12:30:00

Please log in to view news